Product information and disease descriptionPlace of product in therapyApproaches to treatment
Care management intervention strategies
5 evidence topics · 2 sources
Monitoring for conversion to neovascular AMD during complement inhibitor therapy
“If an eye develops nAMD during GA treatment, nAMD treatment will need to be initiated if there are signs of exudation in the macula.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Combined GA and nAMD treatment is both feasible and safe based on pivotal clinical trials, but injections may need to be provided either on different clinical visits or separated by approximately 30 min if performed on the same day to minimize the risk of excessive intraocular pressure elevation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Self-monitoring and electronic home monitoring
Follow-up visits: history and examination
“Changes in medications and nutritional supplements” (opens the source at this quote in a new tab)
“Visual acuity at distance with correction” (opens the source at this quote in a new tab)
“As with many diseases, the severity and rate of progression will vary from patient to patient. Therefore, adjustments to follow-up frequency should be considered depending on the identification of signs of increased risk, such as advanced age, family history, smoking history, and whether the patient is monocular.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient education and shared decision-making
“Additionally, the physician should educate the patient with regard to GA progression and treatment expectations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, the treating physician should educate patients on symptoms that may signify occurrence of adverse events, such as pain, new visual changes, or new floaters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment selection and discontinuation for approved complement inhibitors
“In general, treatment decisions are influenced by patient symptoms, visual acuity, age, fellow-eye status, and ocular comorbidities, as well as the discretion of the physician and patient to conduct a comprehensive personalized risk-benefit assessment that is guided by a general evidence-based treatment algorithm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Several circumstances may warrant discontinuation of GA treatment, such as the occurrence of severe adverse events including endophthalmitis, ischemic optic neuropathy, sustained elevation of intraocular pressure, and significant, nontransient intraocular inflammation, especially if associated with any retinal vasculitis or occlusive vasculitis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, severe central vision loss may represent a scenario where ongoing treatment risks or burdens may not significantly outweigh any potential benefits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote